nach oben

Erschienen in:

23.07.2022 | Original Article

Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway

verfasst von: Huijie Miao, Yajun Geng, Yang Li, Shijie Tang, Feiling Feng, Weijian Li, Yongsheng Li, Liguo Liu, Rui Zhang, Shimei Qiu, Ying Wu, Zeyu Wang, Ziyi Wang, Ziyu Shao, Ke Liu, Lu Zou, Mao Yang, Yuhao Zhao, Chen Chen, Zhizhen Li, Dadong Zhang, Peng Peng, Xiaoyan Qiang, Frank Wu, Yongning He, Luonan Chen, Dongxi Xiang, Xiaoqing Jiang, Maolan Li, Yun Liu, Yingbin Liu

Erschienen in: Cellular Oncology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to investigate the efficiency of our chemically synthesized TT-00420, a novel spectrum-selective multiple protein kinase inhibitor, in cultured cells and animal models of gallbladder cancer (GBC) and explore its potential mechanism.

Methods

Multiple GBC models were established to assess the anti-tumor efficiency, toxicity, and pharmacokinetics of TT-00420. Integrated transcriptomic, proteomic and phosphoproteomic analysis was conducted to identify potential downstream effectors of TT-00420. Western blotting, qRT-PCR, nuclear-cytoplasm separation, and immunofluorescence were performed to confirm the multi-omic results and explore the molecular mechanism of TT-00420. Immunohistochemistry was used to detect FGFR1 and p-FGFR1 expression levels in GBC samples. Autodock software was utilized to investigate the potential binding mode between the TT-00420 and the human FGFR1.

Results

We found that TT-00420 exerted potent growth inhibition of GBC cell lines and multiple xenograft models. Treatment of mice with 15 mg/kg TT-00420 via gavage displayed a half-life of 1.8 h in the blood and rapid distribution to the liver, kidneys, lungs, spleen, and tumors at 0.25 h, but no toxicity to these organs over 2 weeks. Multi-omic analysis revealed c-Jun as a potential downstream effector after TT-00420 treatment. Mechanistically, TT-00420 showed rigorous ability to block FGFR1 and its downstream JNK-JUN (S63/S73) signaling pathway, and induce c-Jun S243-dependent MEK/ERK reactivation, leading to FASLG-dependent tumor cell death. Finally, we found that FGFR1 and p-FGFR1 expression was elevated in GBC patients and these levels correlated with decreased patient survival.

Conclusions

TT-00420 shows potent antitumor efficacy and may serve as a novel agent to improve GBC prognosis.

Nur mit Berechtigung zugänglich

M. Rakic, L. Patrlj, M. Kopljar, R. Klicek, M. Kolovrat, B. Loncar et al., Gallbladder cancer. Hepatobiliary Surg Nutr. 3, 221–226 (2014)PubMedPubMedCentral

M.A. Schmidt, L. Marcano-Bonilla, L.R. Roberts, Gallbladder cancer: epidemiology and genetic risk associations. Chin Clin Oncol. 8, 31 (2019)PubMedCrossRef

T. Ren, Y. Li, X. Zhang, Y. Geng, Z. Shao, M. Li et al., Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study. BMJ Open 11, e038634 (2021)PubMedPubMedCentralCrossRef

T. Ren, Y.S. Li, Y.J. Geng, M.L. Li, X.S. Wu, W.W. Wu et al., Analysis of treatment modalities and prognosis of patients with gallbladder cancer in China from 2010 to 2017. Zhonghua Wai Ke Za Zhi. 58, 697–706 (2020)PubMed

T. Ren, Y.S. Li, X.Y. Dang, Y. Li, Z.Y. Shao, R.F. Bao et al., Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: Results from 24 hospitals in China. World J Gastrointest Surg. 13, 176–186 (2021)PubMedPubMedCentralCrossRef

C. Boutros, M. Gary, K. Baldwin, P. Somasundar, Gallbladder cancer: past, present and an uncertain future. Surg Oncol. 21, e183–e191 (2012)PubMedCrossRef

X-Y. Cui, X-C. Li, J-J. Cui, X-S. Wu, L. Zou, X-L. Song et al., Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen. Hepatobiliary Surg. Nutr. 10, 498–506 (2021)

A. Sharma, B. Kalyan Mohanti, S. Pal Chaudhary, V. Sreenivas, R. Kumar Sahoo, N. Kumar Shukla et al., Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial. Eur J Cancer. 123, 162–170 (2019)PubMedCrossRef

J.S. Jang, H.Y. Lim, I.G. Hwang, H.S. Song, N. Yoo, S. Yoon et al., Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol. 65, 641–647 (2010)PubMedCrossRef

10.

L. Zou, X. Li, X. Wu, J. Cui, X. Cui, X. Song et al., Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. BMC Cancer 21, 818 (2021)PubMedPubMedCentralCrossRef

11.

R.T. Shroff, M.M. Javle, L. Xiao, A.O. Kaseb, G.R. Varadhachary, R.A. Wolff et al., Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 5, 824–830 (2019)PubMedPubMedCentralCrossRef

12.

J. Valle, H. Wasan, D. H. Palmer, D. Cunningham, A. Anthoney, A. Maraveyas, S. Madhusudan, T. Iveson, S. Hughes, S. P. Pereira, M. Roughton, J. Bridgewater, for the ABC-02 Trial Investigators. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N. Engl. J. Med. 362:1273–1281 (2010)

13.

X. Song, Y. Hu, Y. Li, R. Shao, F. Liu, Y. Liu, Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 5, 230 (2020)PubMedPubMedCentralCrossRef

14.

B.I. Rini, S.K. Pal, B.J. Escudier, M.B. Atkins, T.E. Hutson, C. Porta et al., Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 21, 95–104 (2020)PubMedCrossRef

15.

J. Ricke, H.J. Klumpen, H. Amthauer, I. Bargellini, P. Bartenstein, E.N. de Toni et al., Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 71, 1164–1174 (2019)PubMedCrossRef

16.

A. Burchert, G. Bug, L.V. Fritz, J. Finke, M. Stelljes, C. Rollig et al., Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 38, 2993–3002 (2020)PubMedCrossRef

17.

J.C. Yang, S.M. Gadgeel, L.V. Sequist, C.L. Wu, V.A. Papadimitrakopoulou, W.C. Su et al., Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 14, 553–559 (2019)PubMedCrossRef

18.

T. Seto, T. Kato, M. Nishio, K. Goto, S. Atagi, Y. Hosomi et al., Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15, 1236–1244 (2014)PubMedCrossRef

19.

H. Saito, T. Fukuhara, N. Furuya, K. Watanabe, S. Sugawara, S. Iwasawa et al., Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 20, 625–635 (2019)PubMedCrossRef

20.

K. Nakagawa, E.B. Garon, T. Seto, M. Nishio, S. Ponce Aix, L. Paz-Ares et al., Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655–1669 (2019)PubMedCrossRef

21.

S.J. Lubner, M.R. Mahoney, J.L. Kolesar, N.K. Loconte, G.P. Kim, H.C. Pitot et al., Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 28, 3491–3497 (2010)PubMedPubMedCentralCrossRef

22.

H. Horiuchi, H. Kawamata, T. Fujimori, Y. Kuroda. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int. J. Oncol. 23(4), 957–63 (2003)

23.

K. Kiguchi, L. Ruffino, T. Kawamoto, T. Ajiki, J. DiGiovanni. Chemopreventive and Therapeutic Efficacy of Orally Active Tyrosine Kinase Inhibitors in a Transgenic Mouse Model of Gallbladder Carcinoma. Clin. Cancer Res. 11(15), 5572–80 (2005)

24.

L-X. Fu, Q-W Lian, J-D. Pan, Z-L. Xu, T-M. Zhou, B. Ye. JAK2 tyrosine kinase inhibitor ag490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling. J Biol Regul Homeost Agents. 31(1), 51–58 (2017)

25.

Y. Zhang, C. Zuo, L. Liu, Y. Hu, B. Yang, S. Qiu et al., Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer. J Hepatol. 75, 1128–1141 (2021)PubMedCrossRef

26.

F. Liu, Y. Li, D. Ying, S. Qiu, Y. He, M. Li et al., Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder. Signal Transduct Target Ther. 6, 55 (2021)PubMedPubMedCentralCrossRef

27.

M. Li, Z. Zhang, X. Li, J. Ye, X. Wu, Z. Tan et al., Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 46, 872–876 (2014)PubMedCrossRef

28.

M. Li, F. Liu, Y. Zhang, X. Wu, W. Wu, X.A. Wang et al., Whole-genome sequencing reveals the mutational landscape of metastatic small-cell gallbladder neuroendocrine carcinoma (GB-SCNEC). Cancer Lett. 391, 20–27 (2017)PubMedCrossRef

29.

M. Li, F. Liu, F. Zhang, W. Zhou, X. Jiang, Y. Yang et al., Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut 68, 1024–1033 (2019)PubMedCrossRef

30.

P. Peng, G. Li, X. Qiang, Y. Tian, Q. Yu, E. Marangoni, F. Wu. TT-00420, a novel multiple kinase inhibitor to treat TNBC. American Association for Cancer Research, (2019)

31.

M.E. Ritchie, B. Phipson, D. Wu, Y. Hu, C.W. Law, W. Shi et al., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015)PubMedPubMedCentralCrossRef

32.

S. Tyanova, T. Temu, J. Cox, The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc. 11, 2301–2319 (2016)PubMedCrossRef

33.

S. Tyanova, J. Cox, Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research. Methods Mol Biol. 1711, 133–148 (2018)PubMedCrossRef

34.

M.V. Kuleshov, M.R. Jones, A.D. Rouillard, N.F. Fernandez, Q. Duan, Z. Wang et al., Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016)PubMedPubMedCentralCrossRef

35.

D. Seeliger, B.L. de Groot, Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 24, 417–422 (2010)PubMedPubMedCentralCrossRef

36.

E. Shaulian, AP-1–The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal. 22, 894–899 (2010)PubMedCrossRef

37.

G. Raivich, c-Jun expression, activation and function in neural cell death, inflammation and repair. J Neurochem. 107, 898–906 (2008)PubMed

38.

Q. Meng, Y. Xia, c-Jun, at the crossroad of the signaling network. Protein Cell. 2, 889–898 (2011)PubMedPubMedCentralCrossRef

39.

E. Shaulian, M. Karin. AP-1 in cell proliferation and survival. Oncogene. 20(19), 2390–400 (2001)

40.

E. Shaulian, M. Karin. AP-1 as a regulator of cell life and death. Nat. Cell. Biol. 4(5), E131–6 (2002)

41.

L. Gorecki, M. Andrs, M. Rezacova, J. Korabecny, Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther. 210, 107518 (2020)PubMedCrossRef

42.

J.J. Lin, A.T. Shaw, Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer. 2, 350–364 (2016)PubMedPubMedCentralCrossRef

43.

B.C. Medeiros, J. Possick, M. Fradley, Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Rev. 32, 289–299 (2018)PubMedCrossRef

44.

G. Shen, F. Zheng, D. Ren, F. Du, Q. Dong, Z. Wang et al., Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 11, 120 (2018)PubMedPubMedCentralCrossRef

45.

L. Huang, S. Jiang, Y. Shi, Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J Hematol Oncol. 13, 143 (2020)PubMedPubMedCentralCrossRef

46.

S. Qin, A. Li, M. Yi, S. Yu, M. Zhang, K. Wu, Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 12, 27 (2019)PubMedPubMedCentralCrossRef

47.

E. Rassy, R. Flippot, L. Albiges, Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 12, 1758835920907504 (2020)PubMedPubMedCentralCrossRef

48.

A. Spallanzani, G. Orsi, K. Andrikou, F. Gelsomino, M. Rimini, L. Riggi et al., Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 18, 1069–1076 (2018)PubMedCrossRef

49.

Z. Xue, D.J. Vis, A. Bruna, T. Sustic, S. van Wageningen, A.S. Batra et al., MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 28, 719–729 (2018)PubMedPubMedCentralCrossRef

50.

A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, D. Zecchin et al., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012)PubMedCrossRef

51.

C. Sun, S. Hobor, A. Bertotti, D. Zecchin, S. Huang, F. Galimi et al., Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7, 86–93 (2014)PubMedCrossRef

52.

R.B. Corcoran, H. Ebi, A.B. Turke, E.M. Coffee, M. Nishino, A.P. Cogdill et al., EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012)PubMedPubMedCentralCrossRef

53.

S. Karaman, V. M. Leppanen, K. Alitalo. Vascular endothelial growth factor signaling in development and disease. Development. 145(14), dev151019 (2018)

54.

M. Simons, E. Gordon, L. Claesson-Welsh, Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 17, 611–625 (2016)PubMedCrossRef

55.

W.H. Toh, M.M. Siddique, L. Boominathan, K.W. Lin, K. Sabapathy, c-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem. 279, 44713–44722 (2004)PubMedCrossRef

56.

A. Skopelitou, M. Hadjiyannakis, D. Dimopoulos, S. Kamina, O. Krikoni, V. Alexopoulou, C. Rigas, N. J. Agnantis. p53 and c-jun Expression in Urinary Bladder Transitional Cell Carcinoma: Correlation with Proliferating Cell Nuclear Antigen (PCNA) Histological Grade and Clinical Stage. Eur Urol. 31(4), 464–71 (1997)

Titel: Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway
verfasst von: Huijie Miao
Yajun Geng
Yang Li
Shijie Tang
Feiling Feng
Weijian Li
Yongsheng Li
Liguo Liu
Rui Zhang
Shimei Qiu
Ying Wu
Zeyu Wang
Ziyi Wang
Ziyu Shao
Ke Liu
Lu Zou
Mao Yang
Yuhao Zhao
Chen Chen
Zhizhen Li
Dadong Zhang
Peng Peng
Xiaoyan Qiang
Frank Wu
Yongning He
Luonan Chen
Dongxi Xiang
Xiaoqing Jiang
Maolan Li
Yun Liu
Yingbin Liu
Publikationsdatum: 23.07.2022
Verlag: Springer Netherlands
Erschienen in: Cellular Oncology / Ausgabe 4/2022
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-022-00692-7

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry

Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models

AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis

Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer

The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma

VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie